Topics

Orbsen Therapeutics Limited Company Profile

14:49 EDT 19th September 2019 | BioPortfolio


News Articles [949 Associated News Articles listed on BioPortfolio]

Orbsen Therapeutics Moves Into New Headquarters in Galway, Ireland

Progress in company's product pipeline requires move to larger facilities GALWAY, Ireland (PRWEB) April 02, 2019 Orbsen Therapeutics, a biotechnology company focused on the discovery, development...

Aptevo Therapeutics Receives $4.3 Million Milestone Payment From Saol International Limited

SEATTLE, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today the rec...

Athenex Announces Appointment of Dr. Daniel Von Hoff as Chairman of the Scientific Advisory Board of Axis Therapeutics Limited

BUFFALO, N.Y., March 28, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies f...

Recommended Acquisition of Nightstar Therapeutics plc by Tungsten Bidco Limited, a Wholly-Owned Subsidiary of Biogen Switzerland Holdings GmbH; Posting of Scheme Document

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR R...

VINTAGE PEN PIERRE CARDIN SIGMA – ALDRICH ADVERTISING LIMITED PRESENTATION BOX

EUR 7.31 (0 Bids)End Date: Wednesday Jun-19-2019 23:33:29 ISTBid now | Add to watch list Biotech365 : VINTAGE PEN PIERRE CARDIN SIGMA – ALDRICH ADVERTISING LIMITED PRESENTATION BOX BioMarke...

Fagron NV: Disclosure of received notification

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 11 April 2019 - 7:00am CET Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major sharehold...

Quotient Limited to Participate in the Jefferies 2019 Healthcare Conference

JERSEY, Channel Islands, May 21, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company’s Chief Financial Officer, Chri...

Quotient Limited Receives European CE Mark for its Initial IH Microarray

JERSEY, Channel Islands, May 01, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announce...

Drugs and Medications [60 Associated Drugs and Medications listed on BioPortfolio]

Kynamro [kastle therapeutics, llc]

NA

Olopatadine hydrochloride [somerset therapeutics, llc]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

Adenosine [wockhardt limited]

Adenosine Injection, USP FOR RAPID BOLUS INTRAVENOUS USE

Felodipine [wockhardt limited]

Felodipine Extended-Release Tablets, USP Rx only

Ranitidine [wockhardt limited]

Ranitidine Syrup (Ranitidine Oral Solution, USP)

PubMed Articles [445 Associated PubMed Articles listed on BioPortfolio]

Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics.

There is mounting evidence supporting the use of biologic therapeutics for the management of noninfectious uveitis (NIU). This review highlights: biologics with documented efficacy in NIU; agents with...

CRISPR: a promising tool for lipid physiology and therapeutics.

The purpose is to review recent progress in applying the CRISPR/Cas9 system to lipid metabolism and therapeutics.

Advancing Nucleic Acid Therapeutics by Setting Uniform Standards for Experimental Controls.

THE UROLOGY MATCH PROCESS AND THE LIMITED VALUE OF POST-INTERVIEW COMMUNICATION FOR PROGRAM DIRECTORS.

To understand the urology Match process from the perspective of residency program directors, with a particular focus on the role of post-interview communication. Recent surveys of urology applicants r...

Antiglaucoma EP Agonists: A Long Road That Led Somewhere.

For >2 decades, EP agonists have been the subject of antiglaucoma research and development by scientists in industry and academia around the world. The road has led to the recent approval of the first...

Clinical Trials [186 Associated Clinical Trials listed on BioPortfolio]

Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy

The purpose of the study is to assess long-term side effects from subjects who receive a Fate Therapeutics genetically modified NK cell product. Subjects who previously took part in a Fate...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

Companies [1452 Associated Companies listed on BioPortfolio]

Orbsen Therapeutics

Orbsen Therapeutics, Ltd. is a leading company in the development of regenerative medicine therapies across a range of diseases and medical conditions. Founded in 2006, Orbsen The...

Orbsen Therapeutics Limited

Immunocore Limited

Immunocore Limited is developing innovative biological therapeutics to treat a range of cancers, chronic viral infections and diabetes. Immunocore is a privately owned biotechnology company located ...

Millendo Therapeutics, Inc.

Millendo Therapeutics is focused on developing a portfolio of disease-modifying treatments for endocrine diseases caused by hormone dysregulation. Our product candidates seek to i...

Circadian Technologies Limited

Circadian Technologies Limited is an emerging leader in the field of angiogenesis-based treatments for cancer. Focusing on a class of drug targets called Vascular Endothelial Growth Factors (VEGFs),...

More Information about "Orbsen Therapeutics Limited" on BioPortfolio

We have published hundreds of Orbsen Therapeutics Limited news stories on BioPortfolio along with dozens of Orbsen Therapeutics Limited Clinical Trials and PubMed Articles about Orbsen Therapeutics Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Orbsen Therapeutics Limited Companies in our database. You can also find out about relevant Orbsen Therapeutics Limited Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks



Searches Linking to this Company Record